| Updates to existing prior authorization programs | |||
| Drug | Plan | Eff. date | Policy & additional information |
| Forteo (teriparatide), Teriparatide (teriparatide), Tymlos (abaloparatide) | Harvard Pilgrim Health Care Commercial, Tufts Health Plan Commercial, Tufts Health Direct | 11/1/2024 | Parathyroid Hormones |
| Repatha, Praluent, Nexletol, Nexlizet | Harvard Pilgrim Health Care Commercial, Tufts Health Plan Commercial, Tufts Health Direct | 11/1/2024 | Lipid Lowering Agents |
| Vowst (fecal microbiota spores, live-brpk) | Harvard Pilgrim Health Care Commercial, Tufts Health Plan Commercial, Tufts Health Direct | 8/13/2024 | Vowst (fecal microbiota spores, live-brpk) |
| Nexletol (bempedoic acid) and Nexlizet (bempedoic acid/ezetimibe) | Tufts Health RITogether | 11/1/2024 | Nexletol (bempedoic acid) and Nexlizet (bempedoic acid/ezetimibe) |
| Proton Pump Inhibitors (PPIs) | Harvard Pilgrim Health Care Commercial, Tufts Health Plan Commercial, Tufts Health Direct | 11/1/2024 | Proton Pump Inhibitors (PPIs) |
| Tarpeyo | Tufts Health RITogether | 11/1/2024 | Tarpeyo |
Annmarie Dadoly,
Senior Manager, Provider Communications
Joseph O’Riordan,
Editor
Susan Panos, Ellen Gustavson, Ryan Francis, Stephen Wong,
Writers
Kristin Edmonston,
Production Coordinator
Kristina Cicelova,
Graphic Designer